Influenza: Time for a different perspective?
CSL Seqirus organised the symposium "Influenza: Time for a different perspective?" at Options XI for the Control on Influenza conference, which took place in Belfast on 26-29 September.
Three years ago … What did the start of the COVID pandemic unleash for you?
As we mark the third anniversary of the declaration of the pandemic, Eloise Todd, co-founder of Pandemic Action Network, writes an opinion on the first 100 days of COVID-19.
EU-US conference on Long COVID
This online conference aimed to shed light on perspectives for addressing long COVID in the EU and the US. It brought together experts from medical, public health, health economics disciplines, patient organisations and policymakers.
WHO’s Science in 5 : Influenza
How does the vaccine combat the Influenza virus? How does WHO track influenza across the world to decide the composition of the vaccine? Dr Sylvie Briand also explains why we are seeing a spike in respiratory diseases in Science in 5
WHO Webinar Series on Trust and Pandemic Preparedness
The first webinar in the series reviews the lessons learned at the intersection of trust and different responses to health emergencies including HIV, Ebola and COVID-19.
Respiratory viruses and infection control
Health Europa spoke to Dr Albert Osterhaus about the burden of respiratory infections.
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression
The global surge in the omicron (B.1.1.529) variant has resulted in many individuals with hybrid immunity (immunity developed through a combination of SARS-CoV-2 infection and vaccination).
Persistent SARS-CoV-2 infection in patients seemingly recovered from COVID-19
SARS-CoV-2 infection is clinically heterogeneous, ranging from asymptomatic to deadly.
Two-Years Follow-Up of Symptoms and Return to Work in Complex Post-COVID-19 Patients
Many COVID-19 patients present with severe long-lasting symptoms. They might benefit from a coordination team to manage such complex situations, but late efficacy still needs to be determined.
Stopping epidemics when and where they occur
Governments and the global community must urgently tackle difficult questions about why, how, where, and when diagnostics, treatments, and vaccines are produced, and about who is in control of their availability and distribution.
Universal flu vaccines – soon a reality?
How close are we to a universal flu vaccine? Are universal corona vaccines attainable? What are some of the main challenges facing scientists in their quest to develop these vaccines?
News
Partner Organisations
Vaccination of special-risk groups: A toolkit for pharmacists by the International Pharmaceutical Federation (FIP)
It summarises key information, practice guidelines and additional resources in a very practical manner. The Influenza Diabetes Community (IDC) has contributed to the chapter on people living with diabetes.
